SG11201807040WA - N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer - Google Patents

N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer

Info

Publication number
SG11201807040WA
SG11201807040WA SG11201807040WA SG11201807040WA SG11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA SG 11201807040W A SG11201807040W A SG 11201807040WA
Authority
SG
Singapore
Prior art keywords
international
quinolin
imidazo
propan
pyridyl
Prior art date
Application number
SG11201807040WA
Other languages
English (en)
Inventor
Bernard Barlaam
Kurt Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11201807040WA publication Critical patent/SG11201807040WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
SG11201807040WA 2016-04-07 2017-03-30 N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer SG11201807040WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201605958 2016-04-07
PCT/EP2017/057624 WO2017174446A1 (fr) 2016-04-07 2017-03-30 Oxyde de n,n-diméthyl-3-[[5-(3-méthyl-2-oxo-1-tétrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine utilisé comme modulateur de la protéine kinase atm (ataxia telangiectasia mutated) pour traiter le cancer

Publications (1)

Publication Number Publication Date
SG11201807040WA true SG11201807040WA (en) 2018-09-27

Family

ID=58461335

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807040WA SG11201807040WA (en) 2016-04-07 2017-03-30 N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer

Country Status (14)

Country Link
US (1) US20190119270A1 (fr)
EP (1) EP3440079A1 (fr)
JP (1) JP2019513730A (fr)
KR (1) KR20180132804A (fr)
CN (1) CN108834414A (fr)
AU (1) AU2017247558A1 (fr)
BR (1) BR112018070229A2 (fr)
CA (1) CA3015953A1 (fr)
EA (1) EA201891866A1 (fr)
IL (1) IL261558A (fr)
MA (1) MA44603A (fr)
MX (1) MX2018012255A (fr)
SG (1) SG11201807040WA (fr)
WO (1) WO2017174446A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109045042A (zh) * 2018-09-21 2018-12-21 上海交通大学医学院附属上海儿童医学中心 Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用
WO2021260580A1 (fr) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de l'atm
EP3992191A1 (fr) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Dérivés d'imidazo[4,5-c]quinoline et leur utilisation en tant qu'inhibiteurs de kinase atm

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN103030637A (zh) * 2011-10-10 2013-04-10 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
NO2714752T3 (fr) * 2014-05-08 2018-04-21

Also Published As

Publication number Publication date
MX2018012255A (es) 2019-02-07
JP2019513730A (ja) 2019-05-30
AU2017247558A1 (en) 2018-09-13
EA201891866A1 (ru) 2019-04-30
CN108834414A (zh) 2018-11-16
KR20180132804A (ko) 2018-12-12
CA3015953A1 (fr) 2017-10-12
WO2017174446A1 (fr) 2017-10-12
BR112018070229A2 (pt) 2019-01-29
US20190119270A1 (en) 2019-04-25
MA44603A (fr) 2019-02-13
IL261558A (en) 2018-10-31
EP3440079A1 (fr) 2019-02-13

Similar Documents

Publication Publication Date Title
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201903182XA (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201901716TA (en) Adenovirus armed with bispecific t cell engager (bite)
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201808125RA (en) Methods for solid tumor treatment
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408303WA (en) Adhesive compositions of propylene-based and ethylene-based polymers
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201805368YA (en) Anthelmintic depsipeptide compounds
SG11201906222WA (en) Jak1 selective inhibitors
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201408509PA (en) Racecadotril lipid compositions
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same
SG11201900486WA (en) Treatment and prevention of sleep disorders
SG11201804587QA (en) Isoindole compounds
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201807040WA (en) N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer